Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

Abstract Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and children ≥ 1 month old, and relapsed or refractory CD33 + AML in adults and children ≥ ...

Full description

Bibliographic Details
Main Authors: Jorge E. Cortes, Marcos de Lima, Hervé Dombret, Elihu H. Estey, Sergio A. Giralt, Pau Montesinos, Christoph Röllig, Adriano Venditti, Eunice S. Wang
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Journal of Hematology & Oncology
Subjects:
Acute myeloid leukemia
Adverse events
Gemtuzumab ozogamicin
Treatment management
VOD/SOS
Online Access:http://link.springer.com/article/10.1186/s13045-020-00975-2

Internet

http://link.springer.com/article/10.1186/s13045-020-00975-2

Similar Items